Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Logo

The stock of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) registered a decrease of 9.29% in short interest. DFFN’s total short interest was 598,600 shares in December as published by FINRA. Its down 9.29% from 659,900 shares, reported previously. With 145,400 shares average volume, it will take short sellers 4 days to cover their DFFN’s short positions.

The stock increased 4.04% or $0.0097 during the last trading session, reaching $0.2497. About 55,031 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 72.86% since December 7, 2017 and is downtrending. It has underperformed by 88.48% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $12.65 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

More notable recent Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) news were published by: Seekingalpha.com which released: “Diffusion Pharmaceuticals (DFFN) CEO David Kalergis Hosts Analyst Day – Slideshow – Seeking Alpha” on May 23, 2017, also Globenewswire.com with their article: “Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors – GlobeNewswire” published on July 06, 2017, Nasdaq.com published: “Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology – Nasdaq” on November 15, 2018. More interesting news about Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) were released by: Seekingalpha.com and their article: “A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals – Seeking Alpha” published on June 16, 2018 as well as Globenewswire.com‘s news article titled: “Abstract Outlining Pre-Hospital Stroke Study with Diffusion Pharmaceuticals’ TSC To Be Presented at the International Stroke Conference – GlobeNewswire” with publication date: January 24, 2018.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *